Third Company Launch underpinned by promising Opthalmic Programmes

With £96 million Series A financing, Lifescience company developer Syncona has launched Beacon Therapeutics Holdings, a leading ophthalmic gene therapy company focused on restoration and improvement of vision of patients with retinal diseases. Click to read more...

Related Keywords

Nadia Waheed ,Robert Maclaren ,Abraham Scaria ,Beacon Therapeutics Holdings ,Genetic Technologies Corporation ,University Of Oxford ,Oxford Science Enterprises ,Applied Genetic Technologies Corporation ,Beacon Therapeutics ,Beacon Therapeutic ,Chief Executive Officer ,Chief Medical Officer ,Chief Scientific ,